Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2517-2521

  Zhou, Jian ^a   Sulaiman, Zuraidah ^b   Llorin, Ryan M ^c   Hee, Kim Hor ^d   Lee, Lawrence Soon U ^d   Lye, David C ^c,d   Fisher, Dale A ^b,d   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Maximum likelihood expectation maximization; Monte Carlo simulation; Population modelling

Indexed keywords

CREATININE; ERTAPENEM; ANTIINFECTIVE AGENT; BETA LACTAM;

ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLADDER STONE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG USE; HUMAN; KIDNEY FUNCTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OBSERVATIONAL STUDY; OPEN STUDY; OUTPATIENT; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; PROSTATE ABSCESS; PROSTATE HYPERTROPHY; PROSTATITIS; PYELONEPHRITIS; STEADY STATE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; URINARY TRACT INFECTION; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MIDDLE AGED; SERUM; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; URINARY TRACT INFECTIONS; URINE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CHROMATOGRAPHY, LIQUID; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OUTPATIENTS; PROSPECTIVE STUDIES; SERUM; TANDEM MASS SPECTROMETRY; URINARY TRACT INFECTIONS; URINE; YOUNG ADULT;

EID: 84905986328     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku143     Document Type: Article

References (21)

1. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005; 65: 2151-78.
2. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-44.
3. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-42.
4. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 Suppl 2: ii11-21.
5. Seetoh T, Lye DC, Cook AR et al. An outcomes analysis of outpatient parenteral antibiotic therapy (OPAT) in a large Asian cohort. Int J Antimicrob Agents 2013; 41: 569-73.
6. Yong C, Fisher DA, Sklar GE et al. A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective. Int J Antimicrob Agents 2009; 33: 46-51.
7. Wells WG, Woods GL, Jiang Q et al. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004; 53 Suppl 2: ii67-74.
8. KPC-2-producing Klebsiella pneumoniae in Singapore. J Clin Microbiol 2012; 50: 475-6.
9. Teo JW, La MV, Krishnan P et al. Enterobacter cloacae producing an uncommon class A carbapenemase, IMI-1, from Singapore. J Med Microbiol 2013; 62: 1086-8.
10. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96.
11. Tzouvelekis LS, Markogiannakis A, Psichogiou M et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25: 682-707.
12. Ben-David D, Kordevani R, Keller N et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012; 18: 54-60.
13. Correa L, Martino MD, Siqueira I et al. A hospital-based matched case- control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 2013; 13: 80.
14. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrugresistant infection. J Antimicrob Chemother 2010; 65: 1119-25.
15. Majumdar AK, Musson DG, Birk KL et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002; 46: 3506-11.
16. Musson DG, Majumdar A, Holland S et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chemother 2004; 48: 521-4.
17. Wiskirchen DE, Housman ST, Quintiliani R et al. Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy 2013; 33: 266-74.
18. D'Argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, University of Southern California, 2009.
19. Cardone KE, Grabe DW, Kulawy RW et al. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 2012; 56: 725-30.
20. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 4.0, 2014. http://www.eucast.org/clinical_breakpoints/ (2 March 2014, date last accessed).
21. 14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica 2004; 34: 379-89.